GlassScriptPhysician profile
Patria R Gonzalez
NPI 1730111402
$8,746.19
in general payments reported to CMS, 2019-2025
44 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $1,226 · 2021: $1,430 · 2022: $682 · 2023: $751 · 2024: $1,759 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,586 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.30 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,257.26 | 2021-2025 | |
| Glaxosmithkline, LLC. | $937.16 | 2020-2025 | Trelegy Ellipta, Arexvy, Benlysta |
| Amgen INC. | $601.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Horizon Therapeutics Plc | $468.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.25 | 2019-2025 | Xifaxan, Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $463.79 | 2021-2025 | |
| Pfizer INC. | $309.58 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $291.37 | 2021 | |
| Astellas Pharma US INC | $287.23 | 2020-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $284.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $282.49 | 2019-2024 | |
| Novo Nordisk INC | $248.62 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $241.92 | 2019-2024 | Lokelma, Farxiga |
| Abbott Laboratories | $237.11 | 2023-2025 | Infinity, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $216.77 | 2020-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $216.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $184.27 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $180.99 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $178.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $123.80 | 2022-2024 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $120.99 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.85 | 2019 | |
| Nestle Healthcare Nutrition INC. | $106.38 | 2020-2022 | |
| Madrigal Pharmaceuticals | $101.89 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $89.15 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $74.09 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $71.09 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $63.20 | 2025 | Zoryve |
| Scilex Pharmaceuticals INC. | $61.66 | 2023-2025 | Ztlido |
| Janssen Pharmaceuticals, INC | $60.35 | 2019-2022 | |
| Hologic Sales and Service, LLC | $53.54 | 2023-2025 | Aptima |
| Intra-Sana Laboratories | $52.02 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Dexcom, INC. | $48.32 | 2025 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $42.09 | 2020 | |
| Ge Healthcare | $39.25 | 2020-2021 | |
| Corcept Therapeutics | $24.89 | 2023 | Korlym |
| Sumitomo Pharma America, INC. | $23.41 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.82 | 2020 | |
| Ardelyx, INC. | $19.43 | 2024 | Ibsrela |
| Bausch Health US, LLC | $17.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.09 | 2021 | |
| Mission Pharmacal Company | $15.91 | 2019 | |
| Phadia US INC. | $14.81 | 2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patria Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.